Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Midodrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midodrine SCHEMBL29368755 | 1.00 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL30917926 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (S)-Midodrine SCHEMBL6033144 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL131436 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL29367411 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL399213 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899425 | 0.97 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899416 | 0.97 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41464 | 0.96 | ADRA1A (0.95) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899432 | 0.95 | ADRA1A (0.93) | ADRA1ALMNACYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119970665-A | Midodrine hydrochloride tablet and preparation method thereof | 国药集团川抗制药有限公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| CN-118562357-A | Zinc-rich primer containing hollow glass beads and preparation method thereof | 双塔涂料科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118512430-A | Application of midodrine hydrochloride in medicines for relieving intestinal ischemia reperfusion injury | 南方医科大学南方医院 | 2024-08-20 | — | — | CN | claimed |
| US-20220211645-A1 | Maximizing Distribution and Minimizing Washout of Injectates in Bone and Method for Enhanced Aspirate Extraction | YALE UNIVERSITY | 2022-07-07 | — | — | US | claimed |
| US-20220168301-A1 | METHODS FOR TREATING SYMPTOMATIC ORTHOSTATIC HYPOTENSION | AVALO THERAPEUTICS, INC. | 2022-06-02 | — | — | US | claimed |
| US-20220144754-A1 | PROCESS FOR PREPARATION OF MIDODRINE AND INTERMEDIATES THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-05-12 | — | — | US | claimed |
| EP-3965635-A2 | MAXIMIZING DISTRIBUTION AND MINIMIZING WASHOUT OF INJECTATES IN BONE AND METHOD FOR ENHANCED ASPIRATE EXTRACTION | Yale University (US) | 2022-03-16 | — | — | EP | claimed |
| US-20210322345-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | Vertica Pharma, LLC | 2021-10-21 | — | — | US | claimed |
| WO-2004018409-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF (±) 2-AMINO-N-[2,(S,5-DIMETHOXYPHENYL)-2-HYDROXYETHYL] ACETAMIDE MONOHYDROCHLORIDE | SANMAR SPECIALITY CHEMICALS LTD (IN) | 2004-03-04 | — | — | WO | claimed |
| US-20040002663-A1 | Method and system for use in detecting a cancerous and precancerous pathology | REEVES WILLIAM H (US) | 2004-01-01 | — | — | US | claimed |
| EP-1366759-A1 | TABLETS QUICKLY DISINTEGRATING IN ORAL CAVITY | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-12-03 | — | — | EP | claimed |
| EP-1364659-A1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-26 | — | — | EP | claimed |
| EP-1324805-A1 | METHOD AND SYSTEM FOR NERVE STIMULATION AND CARDIAC SENSING PRIOR TO AND DURING A MEDICAL PROCEDURE | Medtronic, Inc. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030086967-A1 | Rapidly disintegrable tablet containing polyvinyl alcohol | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-05-08 | — | — | US | claimed |
| EP-1260215-A1 | RAPIDLY DISINTEGRABLE TABLET CONTAINING POLYVINYL ALCOHOL | Eisai Co., Ltd. (JP) | 2002-11-27 | — | — | EP | claimed |
| US-6444851-B1 | CATALYTIC HYDROGENOLYSIS OF A 2-DIBENZYLAMINO-N-(2-(2',5'-DIMETHOXYPHENYL)-2-HYDROXYETHYL)ACETAMIDE FORMED BY REACTING A DIBENZYLAMINE AND CHLORO-N-(2-(2',5'-DIMETHOXYPHENYL)-2-HYDROXYETHYL)ACETAMIDE; NONEXPLOSIVE | CHEMAGIS LTD. (IL) | 2002-09-03 | — | — | US | claimed |
| WO-2002026318-A1 | METHOD AND SYSTEM FOR NERVE STIMULATION AND CARDIAC SENSING PRIOR TO AND DURING A MEDICAL PROCEDURE | MEDTRONIC, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322345-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | MTX1, MDK, MTX2 | ADRA1A 155/4885LMNA 3564/4885CYP1A2 439/4885 |
| US-20220168301-A1 | METHODS FOR TREATING SYMPTOMATIC ORTHOSTATIC HYPOTENSION | GRIN2B, GRIN3B, GRIN2C | ADRA1A 237/4885LMNA 4593/4885CYP1A2 4595/4885 |
| US-20220144754-A1 | PROCESS FOR PREPARATION OF MIDODRINE AND INTERMEDIATES THEREOF | POR, QDPR, CYP3A7 | ADRA1A 187/4885LMNA 3165/4885CYP1A2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.